This review assessed the effects of non-steroidal anti-inflammatory drugs (NSAIDs) combined with narcotic or regional analgesia in patients undergoing cardiothoracic surgery. It concluded that NSAID use reduced pain and narcotic consumption, but that there were no significant differences in side-effects and hospital length of stay. The conclusions of this well-conducted review appear reliable.
Data extraction
Two reviewers independently extracted the data. The means and standard deviations of continuous outcomes were extracted, while the odds ratio (OR) and 95% confidence intervals (CIs) were calculated for binary outcomes.
Methods of synthesis
How were the studies combined? Pooled ORs and weighted mean differences (WMDs) were obtained using either a fixed-effect or random-effects model, depending on the presence of statistical heterogeneity. Where possible, analyses were conducted on an intentionto-treat basis. Publication bias was assessed using funnel plots.
How were differences between studies investigated?
The Q-statistic was used to assess heterogeneity (p<0.10 suggested significant statistical heterogeneity). Predefined subgroup analyses assessed: elderly patients (aged over 70); cardiac versus thoracic surgery; patients with pulmonary disease, heart failure or renal failure at baseline; and trials including regional anaesthetic techniques. Sensitivity analyses were conducted to assess the effect of trial quality, publication status and studies without intention-to-treat analyses (assuming a worse-case scenario for missing data).
Results of the review
Twenty RCTs (n=1,065) were included.
The median Jadad score was 3 (range: 0 to 5). There was no evidence of publication bias for any outcome.
Pain scores after 24 hours were significantly reduced in the NSAID group compared with the control group (WMD -0.91, 95% CI: -1.48, -0.34; based on 7 studies). The consumption of morphine-equivalents in the first 24 hours after surgery was also significantly reduced for the NSAID group (WMD -7.67 mg, 95% CI: -8.97, -6.38; based on 13 studies). There was significant heterogeneity for both of these outcomes (I-squared 66% and 70%, respectively). There were no were statistically significant differences between the groups for any of the other outcomes. Subgroup analyses showed a significant difference between thoracic and cardiac surgery for morphine-equivalents consumption. Thoracic patients had a greater reduction in consumption: a mean of 9.55 mg (range: 7.78 to 11.32) compared with 5.31 mg (range: 3.42 to 7.2) for cardiac patients. Sensitivity analyses showed that excluding unpublished trials, lack of intentionto-treat analyses, and study quality did not affect the results.
Cost information
The costs were not reported in any of the studies. Other measures of resource use were insufficiently reported to allow for pooled analyses.
